{"name":"Grupo Espanol Multidisciplinario del Cancer Digestivo","slug":"grupo-espanol-multidisciplinario-del-cancer-digestivo","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"5-Fluoruracil","genericName":"5-Fluoruracil","slug":"5-fluoruracil","indication":"Colorectal cancer","status":"phase_3"},{"name":"Gemcitabine and Erlotinib","genericName":"Gemcitabine and Erlotinib","slug":"gemcitabine-and-erlotinib","indication":"Pancreatic cancer","status":"phase_2"},{"name":"Anti-EGFR or Bevacizumab","genericName":"Anti-EGFR or Bevacizumab","slug":"anti-egfr-or-bevacizumab","indication":"Colorectal cancer","status":"phase_2"},{"name":"Atezolizumab plus Tiraglolumab","genericName":"Atezolizumab plus Tiraglolumab","slug":"atezolizumab-plus-tiraglolumab","indication":"Non-small cell lung cancer, triple-negative breast cancer, and other solid tumors","status":"phase_2"},{"name":"Capecitabine during all Radiotherapy period","genericName":"Capecitabine during all Radiotherapy period","slug":"capecitabine-during-all-radiotherapy-period","indication":"Colorectal cancer","status":"phase_2"},{"name":"Chemotherapy plus monoclonal antibody","genericName":"Chemotherapy plus monoclonal antibody","slug":"chemotherapy-plus-monoclonal-antibody","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"5-Fluoruracil","genericName":"5-Fluoruracil","slug":"5-fluoruracil","phase":"phase_3","mechanism":"5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.","indications":["Colorectal cancer","Gastric cancer","Breast cancer","Pancreatic cancer","Head and neck cancer"],"catalyst":""},{"name":"Gemcitabine and Erlotinib","genericName":"Gemcitabine and Erlotinib","slug":"gemcitabine-and-erlotinib","phase":"phase_2","mechanism":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).","indications":["Pancreatic cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Anti-EGFR or Bevacizumab","genericName":"Anti-EGFR or Bevacizumab","slug":"anti-egfr-or-bevacizumab","phase":"phase_2","mechanism":"Inhibits vascular endothelial growth factor A (VEGFA)","indications":["Colorectal cancer","Non-small cell lung cancer","Breast cancer","Glioblastoma"],"catalyst":""},{"name":"Atezolizumab plus Tiraglolumab","genericName":"Atezolizumab plus Tiraglolumab","slug":"atezolizumab-plus-tiraglolumab","phase":"phase_2","mechanism":"Atezolizumab is a PD-L1 inhibitor that blocks the PD-1/PD-L1 interaction, while Tiraglolumab is a TIGIT inhibitor that blocks the TIGIT/LAG-3 interaction, both of which are involved in immune checkpoint pathways.","indications":["Non-small cell lung cancer, triple-negative breast cancer, and other solid tumors"],"catalyst":""},{"name":"Capecitabine during all Radiotherapy period","genericName":"Capecitabine during all Radiotherapy period","slug":"capecitabine-during-all-radiotherapy-period","phase":"phase_2","mechanism":"Capecitabine is a thymidylate synthase inhibitor.","indications":["Colorectal cancer","Breast cancer"],"catalyst":""},{"name":"Chemotherapy plus monoclonal antibody","genericName":"Chemotherapy plus monoclonal antibody","slug":"chemotherapy-plus-monoclonal-antibody","phase":"phase_2","mechanism":"Chemotherapy plus monoclonal antibody works by targeting cancer cells with a combination of chemotherapy agents and monoclonal antibodies that specifically bind to and destroy cancer cells.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic colorectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":1,"phase_2":5},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}